Brought to you by:
Esprit BTK: Drug-eluting resorbable scaffold poised as first-line therapy for below-the-knee CLTI
This advertorial is sponsored by Abbott. “We now have something on label and FDA [Food and Drug Administration] approved that we can use as a first-line therapy for tibial vessels,” Richard Pin, MD, chief of vascular surgery at Southcoast Health…
Esprit BTK receives Health Canada approval for treating below-the-knee CLTI
Health Canada has authorised the Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of below-the-knee (BTK) chronic limb-threatening ischaemia (CLTI), Abbott revealed today in a press release. Until this recent Health Canada approval for the Esprit BTK system, Abbott…
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form…
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year in LIFE-BTK analysis
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of infrapopliteal artery disease, with investigators predicting more significant results in the longer term. Sharing this finding…
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI treatment
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK everolimus-eluting resorbable scaffold system (Esprit BTK system), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is…
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease, an everolimus-eluting resorbable scaffold was…
JETi registry provides “remarkable results” for peripheral thrombectomy system
Presenting “remarkable results” from the JETi registry—a prospective, multicenter, observational study which collected real-world data on the safety, performance and clinical benefits of the JETi peripheral thrombectomy system—speaker Mahmood K. Razavi, MD, relayed the positive outcomes seen with the “powerful”…
First patients enrolled in SUPERSURG study of Supera peripheral stent system
ID3 Medical Belgium has announced the first two enrollments in the SUPERSURG study to investigate the safety and efficacy of Abbotts’ Supera peripheral stent system versus surgical endarterectomy in treating patients with common femoral artery disease, with and without femoral…
Medical device companies join fight against COVID-19
Medtronic is sharing an older version of its Puritan Bennett ventilator for free in a bid to help ramp up production of the key piece of technology in the management of respiratory illness as COVID-19 overwhelms U.S. hospitals. The medical…